Medical Oncology Portfolio Pathway evidence must prove consultant-level cancer medicine centred on systemic anti-cancer therapy, acute oncology, biomarker/genomic decision making, clinical trials, MDT work, patient communication, quality improvement, MSF, patient feedback, appraisals and Multiple Consultant Reports. It is not a radiotherapy route.
What makes this specialty different?
What assessors are really testing
The GMC Medical Oncology SSG is built around high-level learning outcomes and CiPs. Assessors need to see current capability across the curriculum, not just evidence that you have held a senior oncology job.
The SSG is explicit that recent practice, breadth of cases and triangulated evidence make a stronger application. It also says evidence should show that you can assess and offer a first opinion in any setting and for any age, and that evidence should come from a variety of clinical settings.
How Medical Oncology evidence should read
A strong Medical Oncology Portfolio Pathway application should show current systemic cancer medicine at consultant level. It should not read like a chemotherapy log or a list of clinic templates. Assessors need to understand your role in treatment choice, consent, toxicity management, response assessment, clinical trials, biomarker interpretation, acute oncology, MDT decision making and service governance.
This is especially important for senior doctors who have developed a narrow tumour-site practice. Narrow expertise can be clinically valuable, but the Portfolio Pathway still needs enough breadth to show the curriculum. If your evidence is heavily weighted toward one tumour group, one drug class, or one outpatient setting, you may need to deliberately build acute oncology, inpatient, trial, biomarker, survivorship and service-development evidence around it.
Medical Oncology evidence also needs to show that you can work as a senior independent clinician, not just follow protocols. The strongest examples explain why a regimen was chosen, why a guideline was adapted, how patient factors changed the decision, what alternatives were discussed, and how toxicity or progression was managed.
For the wider evidence framework, read the Portfolio Pathway overview, the four GMC domains, the structured CV guide, the MSF plan, the audit guide, the reflective practice guide and the structured reports guide.
The mistake to avoid
Do not submit a portfolio that says only "I prescribe chemotherapy." Medical Oncology evidence needs to show treatment strategy, consent, toxicity, response assessment, acute oncology, trials, biomarkers, patient communication, governance and independent consultant judgement.
Evidence expectations
The Medical Oncology SSG gives some concrete planning numbers, but it repeatedly stresses quality, breadth and capability coverage over simple upload volume.
The numbers are helpful, but they are not the whole story. Around 100 uploaded documents is a planning guide, not a target to hit blindly. Eighteen SLEs and six DOSTs are useful anchors, but they must still cover the right range of Medical Oncology work. A folder with multiple similar assessments from the same clinic will not feel as strong as one that shows breadth across systemic therapy, acute oncology, MDT work, trials, biomarker decisions and complex patient communication.
Think of each evidence item as part of a triangulated case for independent practice. A DOST may show a systemic therapy decision. A clinic letter may show the communication and plan. A CbD may show clinical reasoning. A consultant report may confirm entrustment. A patient survey may support communication and professionalism. A reflection may show insight into risk, uncertainty or toxicity.
This is also why appraisals and MCRs matter. For senior non-training doctors, there may not be a neat training portfolio. Appraisals, consultant reports, MSF, patient feedback and observed assessments help replace that structure, but only if they are specific, current and mapped to the Medical Oncology curriculum.
What to plan around
SACT evidence
SACT is the spine of Medical Oncology evidence. The strongest portfolios do not just show prescription volume. They show treatment choice, risk-benefit discussion, informed consent, toxicity management, response assessment and safe adaptation of treatment.
What good SACT evidence looks like
Good SACT evidence starts before the prescription. It shows disease status, treatment intent, biomarker or molecular information, previous therapies, co-morbidities, performance status, organ function, patient preference, trial availability and the MDT context. The prescribing decision is only one part of the evidence.
The DOST is particularly useful because it forces the evidence to show treatment choice, consent, prescription review, toxicity grading, dose adjustment, discontinuation where appropriate and response assessment. If you are building a Medical Oncology Portfolio Pathway application, you should deliberately choose DOST cases that show different types of systemic therapy and different decision pressures.
Useful examples might include immunotherapy toxicity, dose modification in frailty, targeted therapy after biomarker testing, treatment outside a straightforward protocol, adjuvant versus palliative intent, trial eligibility, or stopping treatment because the risk-benefit balance has changed. These are the cases where consultant judgement is visible.
SACT evidence that earns its place
Use DOST, clinic letters, CbDs, mini-CEX, prescribing evidence and reflections to show the whole decision.
Treatment strategy
Evidence should show why this regimen was chosen, including disease biology, biomarkers, patient condition and intent.
Risk-benefit discussion
Show communication around benefit, toxicity, alternatives, trial options and patient preference.
Monitor and adapt
Include grading, dose modification, discontinuation, supportive care and response assessment.
Different systemic therapies
Cover chemotherapy, immunotherapy, targeted therapy, hormonal therapy and novel or emerging approaches where relevant.
Acute oncology, trials and biomarkers
Medical Oncology is not only planned outpatient systemic therapy. You also need evidence across acute oncology, deteriorating cancer patients, clinical trials, genomics, biomarkers, survivorship and multi-disciplinary care.
Why acute oncology, trials and biomarkers cannot be bolted on at the end
Medical Oncology is not just planned treatment in clinic. Acute oncology shows how you manage uncertainty, deterioration and complications. Trials show how you understand evidence generation, governance, consent and protocol-driven care. Biomarker and genomic evidence shows how you use precision oncology to shape treatment strategy. These areas need to be present in the portfolio from the beginning, not added as token documents at the end.
For acute oncology, useful evidence might include new presentations of malignancy, malignancy of undefined origin, carcinoma of unknown primary, neutropenic sepsis, spinal cord compression, immunotherapy toxicity, hypercalcaemia, thromboembolic complications, disease progression and end of life decisions. The best examples show triage, investigation, escalation, treatment planning and communication with the wider team.
For trials and biomarkers, the evidence should show more than certificate collection. GCP training is helpful, but it becomes stronger when paired with actual trial involvement, screening, consent, safety reporting, protocol adherence, sub-investigator or principal investigator activity, and patient discussions about trial options or molecularly targeted treatments.
Medical Oncology pathway evidence
These areas are where the Medical Oncology portfolio starts to feel specialty-specific rather than generic.
Acute oncology
Neutropenic sepsis, immunotherapy toxicity, spinal cord compression, hypercalcaemia, SVC obstruction and treatment complications.
GCP and investigator activity
Trial recruitment, sub-investigator or principal investigator work, protocol decisions and research governance.
Biomarkers and genomics
Interpretation of biomarkers, genomic testing, molecular reports and personalised systemic treatment decisions.
Guidelines and protocols
Developing or implementing SACT guidelines, toxicity pathways, diagnostic approaches and service protocols.
Evidence your post itself must produce
A Medical Oncology-friendly post should produce more than clinic letters. It needs to create observed SACT, acute oncology, trial, MDT, governance and consultant-report evidence.
A Medical Oncology-friendly post is one that creates observable, documentable evidence. It should give you SACT responsibility, acute oncology exposure, tumour-site MDTs, trial or research infrastructure, biomarker/genomic decision making, governance, appraisal and consultants who can write specific MCRs. Without those ingredients, even a busy senior role can leave you short of usable Portfolio Pathway evidence.
Before accepting or staying in a role, ask how evidence will actually be generated. Will you have access to DOSTs and consultant-observed assessments? Are you involved in SACT prescribing and treatment changes? Do you see acute oncology and inpatient complications? Are you part of trials or protocol development? Can your consultants comment directly on independent practice? These practical questions determine whether the post is genuinely helpful.
The Medical Oncology job-fit evidence checklist
These are the documents and opportunities your role needs to produce.
A 90-day evidence plan
What to do next
Map the CiPs
Mark each Medical Oncology CiP as strong, partial or missing, with the exact evidence you already have.
Book DOST and SLEs
Arrange observed systemic therapy and CbD/mini-CEX evidence before cases disappear from memory.
Fill trial and AOS gaps
Target acute oncology, trials, GCP, biomarkers, protocol work and survivorship evidence if thin.
Brief MCR writers
Ask consultants whether they can comment across systemic therapy, acute oncology, trials and independent practice.
Download the Medical Oncology evidence map
A two-page checklist for SACT, DOST, acute oncology, trials, biomarkers, MDT, appraisal, feedback and MCR evidence.
Where BDI Consultants fits
BDI Consultants does not sell Portfolio Pathway review packages and this article is not a substitute for GMC or physician specialty guidance. Our recruitment work is different: we help senior doctors find Consultant, Specialist and senior SAS opportunities where Portfolio Pathway progress is understood rather than ignored.
For Medical Oncology, that means looking carefully at whether the post gives you SACT, acute oncology, MDT, trials, biomarkers, governance, appraisal and MCR support.
Official sources used
| Source | Publisher |
|---|---|
| Medical Oncology Specialty Specific Guidance | General Medical Council |
| Medical Oncology curriculum | General Medical Council / Federation |
Frequently asked
Is Medical Oncology Portfolio Pathway separate from Clinical Oncology?
Yes. Medical Oncology is a separate Portfolio Pathway specialty from Clinical Oncology. It focuses on systemic anti-cancer therapy, acute oncology, clinical trials, biomarkers/genomics, cancer medicine, communication, leadership, safety and professional capability.
Do Medical Oncology applicants need MRCP or SCE?
The Medical Oncology SSG says applicants should evidence core internal medicine capability to the level of two years of Internal Medicine stage 1 training, often through MRCP(UK) or comparable assessment. Specialty Certificate Examination evidence is also listed as relevant specialist evidence.
What does the Medical Oncology SSG say about evidence volume?
It says most applications are expected to include around 100 electronically uploaded documents, but the number of documents is less important than quality, breadth and whether the evidence addresses the required learning outcomes and CiPs.
How many DOSTs are expected for Medical Oncology?
The Medical Oncology SSG lists Direct Observation of Systemic Therapy as evidence of SACT competence and indicates 6 DOSTs. They should demonstrate treatment choice, consent, prescription review, toxicity management, response assessment and breadth across systemic therapies.
What kind of role best supports Medical Oncology Portfolio Pathway?
The best role provides broad tumour-site work, SACT prescribing, acute oncology, inpatient/treatment complication management, MDT decision making, trials/GCP, biomarker/genomic decision making, governance, audit/QI and consultants who can provide detailed MCRs or structured reports.
Is research or clinical trial evidence important?
Yes. Medical Oncology has a strong research and trials spine. Evidence may include GCP training, clinical trial involvement, sub-investigator or principal investigator activity, protocol work, data governance and use of trial options in patient discussions.